$3.19
10.14% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CH0329023102
Symbol
ACIU
Sector
Industry

AC Immune SA Stock price

$3.19
-0.01 0.31% 1M
-0.32 9.12% 6M
-1.81 36.20% YTD
+0.19 6.33% 1Y
-2.59 44.81% 3Y
-3.77 54.17% 5Y
-12.47 79.63% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.36 10.14%
ISIN
CH0329023102
Symbol
ACIU
Sector
Industry

Key metrics

Market capitalization $317.98m
Enterprise Value $134.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.67
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 6.79
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth 4,516,931.76%
Revenue (TTM) Revenue $46.86m
EBIT (operating result TTM) EBIT $-42.27m
Free Cash Flow (TTM) Free Cash Flow $50.36m
Cash position $187.18m
EPS (TTM) EPS $-0.45
P/E forward negative
P/S forward 14.45
EV/Sales forward 6.95
Short interest 1.86%
Show more

Is AC Immune SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

AC Immune SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a AC Immune SA forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a AC Immune SA forecast:

Buy
100%

Financial data from AC Immune SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
47 47
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
26% 26%
31%
- Research and Development Expense 70 70
16% 16%
148%
-40 -40
46% 46%
-85%
- Depreciation and Amortization 2.48 2.48
0% 0%
5%
EBIT (Operating Income) EBIT -42 -42
45% 45%
-90%
Net Profit -45 -45
40% 40%
-95%

In millions USD.

Don't miss a Thing! We will send you all news about AC Immune SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AC Immune SA Stock News

Neutral
GlobeNewsWire
4 months ago
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
Positive
Seeking Alpha
4 months ago
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected...
Neutral
GlobeNewsWire
4 months ago
AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for...
More AC Immune SA News

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Head office Switzerland
CEO Andrea Pfeifer
Employees 161
Founded 2003
Website www.acimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today